Methods and compositions suitable for treating acne

Abstract

Methods and compositions suitable for treating acne, disrupting biofilms, and / or killing bacteria contained in biofilms are provided. [Solution] A particular method involves contacting skin requiring such treatment with a composition comprising two α-hydroxy acids and a polyhydroxy acid. Another particular method involves applying a composition comprising a first α-hydroxy acid, a second α-hydroxy acid, and a polyhydroxy acid to a surface having a biofilm. A particular composition is a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer, It contains, and the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition.

Description

[Technical Field]

[0001] Aspects of the present invention generally relate to compositions suitable for the treatment of acne, particularly compositions comprising α-hydroxy acids and polyhydroxy acids. [Background technology]

[0002] Acne disorders are often classified as non-inflammatory or inflammatory types. Non-inflammatory acne is characterized by closed comedones (milia) and open comedones (blackheads), which consist of dense clumps of keratin, sebum, and bacteria that dilate the follicular ducts. Comedones form when the pilosebaceous ducts become blocked and / or when sebum production by the sebaceous glands increases. Following comedone formation, inflammation may occur due to bacterial proliferation and / or excessive sebum production. Typically, the bacteria are anaerobic bacteria such as Propionibacterium acnes (formerly known as Propionibacterium acnes). Inflammatory acne is characterized by papules (pimples), pustules, and nodular cystic lesions, which can lead to scarring. Several factors, including sebum production, hormonal stimulation, clogged pores, and skin pathogens, are thought to play important roles in the pathogenesis of acne. Sebum levels are increased by approximately 70% in subjects with acne compared to control subjects. [Overview of the project] [Problems that the invention aims to solve]

[0003] Many treatments and products have been tried to treat acne, but none have been found to be universally effective, and further treatments are still needed. Furthermore, there is a continuing need to identify acne treatments that are not only effective but also well-tolerated by the skin. [Means for solving the problem]

[0004] One aspect of the present invention is a composition for treating acne, a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer, The composition comprises glycolic acid, gluconolactone, and mandelic acid, with the total amount of these being less than about 15% by weight of the total composition. In one or more embodiments, the composition relates to a composition in which the total amount of glycolic acid, gluconolactone, and mandelic acid is at least about 2% by weight of the total composition. In some embodiments, the glycol is selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof. In one or more embodiments, the composition is in the form of a lotion. In one or more embodiments, the composition is in the form of a lotion. In one or more embodiments, the composition is in the form of a gel. In some embodiments, the composition has a rheometer viscosity of about 2,000 to about 18,000 cPs at 22°C. In one or more embodiments, the composition has a rheometer viscosity of about 8,000 to about 10,000 cPs at 22°C. In some embodiments, the composition has a pH of about 3 to about 5. In one or more embodiments, the composition further comprises about 0.5% to about 5% by weight of salicylic acid. In some embodiments, the composition is substantially free of salicylic acid. In one or more embodiments, the composition is substantially free of lactic acid. In some embodiments, the salt-resistant thickening polymer comprises a sulfonate, acrylate, and / or cellulose moiety. In one or more embodiments, the salt-resistant thickening polymer is selected from the group consisting of polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, and combinations thereof. In some embodiments, the salt-resistant thickening polymer comprises hydroxyethyl cellulose.

[0005] Another aspect of the present invention is a composition for treating acne, a. Glycolic acid in an amount of approximately 2.5% to 7.5% by weight, b. Approximately 1% to 5% by weight of gluconolactone, c. Approximately 1% to 5% by weight of mandelic acid, d. Approximately 2.5% to 7.5% by weight of propylene glycol, e. Approximately 0.5% to 2% by weight of polyacrylate crosspolymer-6, f. Approximately 0.5% to 2% by weight of hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, The present invention relates to a composition comprising glycolic acid, gluconolactone, and mandelic acid, wherein the total amount of these compounds is less than about 12% by weight of the total composition. In one or more embodiments, the composition is in the form of a lotion. In one or more embodiments, the composition is in the form of a gel. In some embodiments, the composition has a rheometer viscosity of about 2,000 to about 18,000 cPs at 22°C. In one or more embodiments, the composition has a rheometer viscosity of about 8,000 to about 10,000 cPs at 22°C. In some embodiments, the composition has a pH of about 3 to about 5. In one or more embodiments, the composition further comprises about 0.5% to about 5% by weight of salicylic acid. In some embodiments, the composition is substantially lactic acid-free.

[0006] Another aspect of the present invention relates to a method for treating acne, the method comprising contacting skin requiring such treatment with a composition comprising a first α-hydroxy acid, a second α-hydroxy acid, and a polyhydroxy acid. In one or more embodiments, the first α-hydroxy acid comprises glycolic acid, the second hydroxy acid comprises mandelic acid, and the polyhydroxy acid comprises gluconolactone. In some embodiments, the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition. In one or more embodiments, the total amount of acids in the composition is less than about 15% by weight of the total composition. In some embodiments, the composition is left on the skin. In one or more embodiments, the composition is in the form of a lotion. In some embodiments, the composition has a pH of about 3 to about 5. In one or more embodiments, the composition further comprises glycols selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof. In some embodiments, the composition is substantially free of lactic acid. In one or more embodiments, the composition is substantially free of salicylic acid.

[0007] Another aspect of the present invention relates to a method for treating acne, the method comprising: a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer, The composition comprises contact with the composition, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition. In some embodiments, the total amount of acids in the composition is less than about 15% by weight of the total composition. In one or more embodiments, the composition is left on the skin. In some embodiments, the composition is in the form of a lotion. In one or more embodiments, the composition has a pH of about 3 to about 5. In some embodiments, the composition further comprises glycols selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, and copolymers and combinations thereof. In one or more embodiments, the composition is substantially free of lactic acid. In some embodiments, the composition is substantially free of salicylic acid. In one or more embodiments, the salt-resistant thickening polymer comprises acrylate and / or cellulose moieties. In some embodiments, the salt-resistant thickening polymer is selected from the group consisting of polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, and combinations thereof.

[0008] Another aspect of the present invention relates to a method for destroying a biofilm or killing bacteria contained in a biofilm, the method comprising applying a composition comprising a first α-hydroxy acid, a second α-hydroxy acid, and a polyhydroxy acid to a surface having a biofilm. In one or more embodiments, the surface is a surface on skin. In some embodiments, the skin has acne. In one or more embodiments, the biofilm contains Propionibacterium acnes bacteria. In some embodiments, the first α-hydroxy acid comprises glycolic acid, the second hydroxy acid comprises mandelic acid, and the polyhydroxy acid comprises gluconolactone. In one or more embodiments, the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition. In some embodiments, the total amount of acids in the composition is less than about 15% by weight of the total composition. In one or more embodiments, the composition is in the form of a lotion. In some embodiments, the composition has a pH of about 3 to about 5. In one or more embodiments, the composition further comprises glycols selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof. In some embodiments, the composition is substantially free of lactic acid. In one or more embodiments, the composition is substantially free of salicylic acid.

[0009] Another aspect of the present invention relates to a method for destroying a biofilm or killing bacteria contained in a biofilm, comprising applying a composition to a surface having a biofilm, wherein the composition is a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer, The composition contains glycolic acid, gluconolactone, and mandelic acid, with the total amount of these being less than about 15% by weight of the total composition, the composition having a pH of about 3 to about 5, and the surface being a surface on skin. In some embodiments, the skin has acne. In one or more embodiments, the biofilm contains Propionibacterium acnes bacteria. In some embodiments, the total amount of acids in the composition is less than about 15% by weight of the total composition. In one or more embodiments, the composition further comprises glycols selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, and copolymers and combinations thereof. In some embodiments, the composition is substantially free of lactic acid. In one or more embodiments, the composition is substantially free of salicylic acid. In some embodiments, the salt-resistant thickening polymer is selected from the group consisting of polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, and combinations thereof. [Modes for carrying out the invention]

[0010] definition "To treat acne" means to reduce or prevent acne or rosacea.

[0011] "Product" refers to the product in its finished packaged form. In one embodiment, the package is a container such as a plastic, metal, or glass tube or jar containing the composition. The product may further include additional packaging such as a plastic or cardboard box for storing such a container. In one embodiment, the product includes instructions for the user to apply the composition to (i) treat acne, or (ii) reduce the appearance of oil or pores on the skin.

[0012] "Sales promotion" means sales promotion, publicity, or marketing. Examples of sales promotion include, but are not limited to, product, in-store, magazine, newspaper, radio, television, Internet, etc. documents, visual messages or oral messages.

[0013] To promote the treatment of acne, examples of such descriptions include, but are not limited to, "treat acne", "treating acne", "prevent acne", "reduce acne lesions, pimples, or eruptions", "reduce the appearance of acne lesions, pimples, or eruptions", "reduce the occurrence of acne and the appearance of acne", "prevent, control or regulate the occurrence of acne and the appearance of acne", and "reduce the occurrence and acne".

[0014] To promote the reduction of the appearance of oil on the skin, examples of such descriptions include, but are not limited to, "reduce the appearance of sebum", "prevent, control or regulate the production of sebum", "reduce sebum", "reduce the appearance of oily / shiny skin", "reduce the appearance of seborrheic skin", and "reduce the gloss on the skin, hair, or scalp". In one embodiment, the composition is applied to skin that does not require treatment for acne (i.e., skin or scalp / hair that is not affected by acne).

[0015] To promote the reduction of the appearance of pores on the skin, examples of such descriptions include, but are not limited to, "reduce the size of pores", "minimize the appearance of pores", "improve the appearance of pores", "reduce the visibility of pores", and "close the pores". In one embodiment, the composition is applied to skin that does not require treatment for acne (i.e., skin that is not affected by acne).

[0016] As used herein, "administered to the skin" or "contacted with the skin" means contacting the area of the skin that requires such treatment, or the area of the skin adjacent to the area of the skin that requires such treatment (e.g., by use of an applicator such as, but not limited to, the hand, or a wipe, tube, roller, spray, or patch).

[0017] As used herein, "composition" means a composition suitable for topical administration to the skin.

[0018] As used herein, "cosmetically acceptable" means that the components so described are suitable for use in contact with the skin without undue toxicity, incompatibility, instability, irritation, allergic response, etc.

[0019] As used herein, "safe and effective amount" means an amount of a compound, carrier, or composition that is sufficient to induce an enhancement of tissue elasticity but low enough to avoid any undesirable adverse side effects. The safe and effective amount of a compound or composition will vary depending on factors such as the area being treated, the age, health and skin type of the end user, the duration and nature of the treatment, the particular compound or composition being administered, the particular cosmetically acceptable carrier being utilized, etc.

[0020] The articles "a," "an," and "the" all refer to the plural in conjunction with the singular.

[0021] The expression "one or more" is synonymous with "at least one" and includes individual components as well as mixtures / combinations.

[0022] Unless otherwise indicated in the Examples or otherwise specified, all numbers expressing amounts of ingredients and / or reaction conditions are to be understood as being modified in all instances by the term "about" which means within + / - 5% of the indicated number.

[0023] All percentages, parts, and ratios herein are based on the total weight of the compositions unless otherwise indicated.

[0024] As used herein, unless otherwise indicated, “substantially absent” or “essentially absent” means that the amount of the component added to the composition is less than about 2% by weight, based on the total weight of the composition. The composition may contain less than about 1%, 0.5%, or 0.1% by weight, or may contain no component at all.

[0025] All publications and patent applications cited herein are incorporated herein by reference for any purpose as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. This disclosure controls whether there is any inconsistency between this disclosure and any incorporated publication or patent.

[0026] Method, use, and composition Various aspects of the present invention relate to methods and compositions suitable for treating acne. In one or more embodiments, the method involves skin requiring such treatment with a composition comprising two α-hydroxy acids and a polyhydroxy acid. That is, in some embodiments, the present invention relates to the use of a composition comprising two α-hydroxy acids and one polyhydroxy acid for the treatment of acne. Surprisingly, combinations of these three acids (in particular, blends of glycolic acid, gluconolactone, and mandelic acid) have been found to be effective in treating acne. In particular, surprisingly, these three acids have been found to be well tolerated by the skin while improving the acne condition (e.g., reduction of acne lesions, improvement of skin texture, increase in skin clarity and uniformity, etc.).

[0027] Furthermore, recent evidence suggests that acne may be associated with the formation of skin biofilms by certain bacteria (e.g., Propionibacterium acnes). Therefore, another aspect of the present invention relates to a method for disrupting biofilms or killing bacteria contained within biofilms. As used herein, the term “disrupting biofilm” means that at least a portion of the bacteria in the biofilm are killed such that the matrix of the biofilm degrades, disperses, or breaks down over time. In some embodiments, the matrix of the biofilm may be degraded during or immediately after exposure of the biofilm to one or more compositions. The method involves applying a composition comprising a first α-hydroxy acid, a second α-hydroxy acid, and a polyhydroxy acid to a surface having a biofilm (e.g., acne-affected skin). Surprisingly, combinations of these three acids (in particular, blends of glycolic acid, gluconolactone, and mandelic acid) have been found to be effective in killing Propionibacterium acnes. In particular, and surprisingly, it was discovered that these three acids can not only kill acne bacteria, but also destroy the biofilms formed by acne bacteria, or otherwise pass through the biofilm matrix and kill the acne bacteria within the biofilm.

[0028] Alpha-hydroxy acids are compounds containing carboxylic acids in which a hydroxyl group is substituted on an adjacent carbon atom. Examples of alpha-hydroxy acids include, but are not limited to, glycolic acid, malic acid, tartaric acid, uric acid, mandelic acid, or any combination of the above. Each alpha-hydroxy acid may be present in amounts ranging from about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 or 5.5 to about 5, 5.5, 6, 6.5, 7 or 7.5% by weight of the total composition.

[0029] In one or more embodiments, at least one of the α-hydroxy acids is glycolic acid. In some embodiments, at least one of the α-hydroxy acids is mandelic acid. In further embodiments, the composition is a blend of glycolic acid and mandelic acid. Glycolic acid is the smallest α-hydroxy acid and has the molecular formula C2H4O3. Glycolic acid is individually well known in the art and is readily available from various commercial sources. Glycolic acid may be present in the composition in amounts ranging from about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 or 5.5 to about 5, 5.5, 6, 6.5, 7 or 7.5% by weight of the total composition. Mandelic acid is an aromatic α-hydroxy acid and has the molecular formula C6H5CH(OH)CO2H. Mandelic acid is individually well known in the art and readily available from various commercial sources. Mandelic acid may be present in the composition in amounts ranging from about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 or 1.5 to about 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5% by weight of the total composition.

[0030] Polyhydroxy acids are acids having multiple hydroxyl groups that can often act as humectants, anti-irritants, and water-retaining agents. Examples of polyhydroxy acids include, but are not limited to, gluconate lactones and aldonic acid lactones, such as aronolactone, altronolactone, gluconolactone, glucoheptonolactone, mannolactone, gulonolactone, idonolactone, galactonolactone, talonolactone, lactobionic acid, maltobionic acid, and tartaric acid. In some embodiments, the polyhydroxy acid includes gluconolactone. Gluconolactone has the molecular formula C6H 10It is a polyhydroxy acid having O6. Gluconolactones are individually well known in the art and readily available from various commercial sources. A polyhydroxy acid (e.g., gluconolactone) may be present in the composition in amounts ranging from about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 or 1.5 to about 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 by weight of the total composition.

[0031] In one or more embodiments, the total amount of α-hydroxy acids and polyhydroxy acids is less than about 15, 14.5, 14, 13.5, 13, 12.5, 12, 11, or 10.5% by weight of the total composition. In some embodiments, the total amount of α-hydroxy acids and polyhydroxy acids is at least about 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10% by weight of the total composition.

[0032] In some embodiments, the composition comprises glycolic acid, mandelic acid, and gluconolactone as α-hydroxy acids and polyhydroxy acids. In one or more embodiments, the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15, 14.5, 14, 13.5, 13, 12.5, 12, 11, or 10.5% by weight of the total composition. In some embodiments, the total amount of glycolic acid, gluconolactone, and mandelic acid is at least about 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10% by weight of the total composition.

[0033] In some embodiments, the composition further comprises a β-hydroxy acid. Exemplary β-hydroxy acids include, but are not limited to, salicylic acid, β-hydroxybutanoic acid, tropic acid, and tretocanic acid. Other suitable β-hydroxy acids are described in 5665776(Yu). In some embodiments, the composition comprises salicylic acid as the β-hydroxy acid. If present, the β-hydroxy acid may be present in amounts ranging from about 0.1, 0.2, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5 or 3 to about 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4 or 5% by weight. In some embodiments, salicylic acid may be present in amounts ranging from about 0.1, 0.2, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5 or 3 to about 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4 or 5% by weight.

[0034] In one or more embodiments, the composition may contain other acids in amounts less than 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, and 0.05. In further embodiments, the composition is substantially free of or does not contain other acids (i.e., does not contain them). In one or more embodiments, the composition may contain salicylic acid in amounts less than 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, and 0.05. In further embodiments, the composition is substantially free of or does not contain salicylic acid (i.e., does not contain it). In one or more embodiments, the composition may contain lactic acid in amounts less than 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, and 0.05. In further embodiments, the composition is substantially free of or does not contain lactic acid (i.e., does not contain it).

[0035] In some embodiments, the total amount of acid in any type of composition is less than 15, 14.5, 14, 13.5, 13, 12.5, 12, 11.5, 11, 10.5, or 10% by weight of the total composition.

[0036] In one or more embodiments, the composition further comprises a glycol. While not bound by any particular theory, glycols are thought to increase the biodelivery of one or more acids. In one or more embodiments, the glycol is selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentalene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof. In further embodiments, the glycol comprises propylene glycol.

[0037] In some embodiments, the composition further comprises a salt-tolerant thickening polymer and / or a dispersion polymer. As used herein, the term “salt-tolerant thickening polymer” refers to a polymer that can increase the viscosity of a composition while maintaining stability in the presence of relatively high concentrations of salt in the formulation. In some embodiments, a salt-tolerant thickening polymer can increase the viscosity of a composition having a salt concentration greater than about 2.0%. In particular, a salt-tolerant thickening polymer can withstand relatively high concentrations of salt and can function as a thickener at relatively low pH (e.g., about 4.5 or less than 4). Since salts are derived from the ionized form of acids, the salt content is related to pH. Therefore, for example, one or more of the compositions described herein may have a pK of an acid (e.g., mandelic acid, glycolic acid, gluconolactone, salicylic acid, etc.). a It is prepared at a pH of 3.8–4.0, exceeding the specified value. Therefore, more than 50% of the acid is present in the formulation as a salt. As used herein, the term “dispersion polymer” refers to a polymer that enables the suspension of particles and / or droplets.

[0038] The salt-resistant thickening polymer may be crosslinked or not. In one or more embodiments, the salt-resistant thickening polymer may include a polyacrylate thickener, a polyacrylamide thickener, or a crosslinked copolymer containing an acrylate and / or acrylamide moiety. In one or more embodiments, the salt-resistant thickening polymer contains a sulfonate group. In one or more embodiments, the salt-resistant thickening polymer contains structural units derived from acrylamide alkylsulfonic acid or a salt thereof. In such embodiments, the salt-resistant thickening polymer may include the following: - A polymer based on 2-acrylamido-2-methylpropanesulfonic acid and / or a salt thereof, sold under the name Aristoflex (trademark), as described in European Patent No. 0816403, European Patent No. 1116733, and European Patent No. 1069142. - Polymers based on 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid and / or salts thereof, as described in U.S. Patent No. 10849845(B2). - Polymers containing structure (I):

[0039] [ka] (In the formula, R 3 (wherein Y is a hydrogen atom, methyl, or ethyl; Y is an alkylene group having 1 to 9 carbon atoms; and X is an ammonium, alkali metal, or alkaline earth metal ion). The salt-resistant thickening polymer may also contain other neutral and / or hydrophobic monomers.

[0040] Suitable neutral monomers include, but are not limited to, N,N-dialkylacrylamides, where each alkyl group contains 1 to 4 carbon atoms, and more specifically, N,N-dimethylacrylamide, N,N-diethylacrylamide, N,N-dipropylacrylamide, or N,N-diisopropylacrylamide.

[0041] Suitable hydrophobic monomers (also called “associative” monomers) for use in hydrophobically modified polymer electrolytes are described, for example, in U.S. Patents No. 5,292,843, No. 6,897,253, No. 7,288,616, No. 3,035,004 and U.S. Patent Application Publication 2006 / 0270563, the contents of which are incorporated herein by reference in their entirety.

[0042] As used herein, “hydrophobic moiety” means a nonpolar moiety comprising at least one of the following (a) to (c): (a) a carbon-carbon chain of at least five carbons, none of which are carbonyl carbons or have hydrophilic moieties directly bonded to them; (b) two or more alkylsiloxy groups (-[Si(R)2-O]-); and / or (c) two or more consecutive oxypropylene groups. The hydrophobic moiety may be or may comprise linear, cyclic, aromatic, saturated, or unsaturated groups. In certain preferred embodiments, the hydrophobic moiety comprises a carbon chain of at least six carbons, more preferably seven carbons, none of which have hydrophilic moieties directly bonded to them. Certain other preferred hydrophobic moieties comprise a carbon chain of about eight or more carbon atoms, more preferably about ten or more carbon atoms, none of which have hydrophilic moieties directly bonded to them. Examples of hydrophobic functional groups include ester, ketone, amide, carbonate, urethane, carbamate, or xanthate functional groups, which have a carbon chain of at least four carbon atoms incorporated into or bonded to them, and none of the four carbon atoms have a hydrophilic portion to which they are directly bonded. Other examples of hydrophobic groups include poly(oxypropylene), poly(oxybutylene), poly(dimethylsiloxane), and fluorinated hydrocarbon groups, which contain a carbon chain of at least four carbon atoms, and none of the four carbon atoms have a hydrophilic portion to which they are directly bonded.

[0043] As used herein, “hydrophilic moiety” is any polar, anionic, cationic, zwitterionic, or nonionic group. Non-limiting examples include anionic substances such as sulfates, sulfonates, carboxylic acids / carboxylates, phosphates, and phosphonates; cationic substances such as ammonium, pyridinium, imidazolinium, amidinium, and poly(ethyleneiminium), including amino, mono-, di-, and trialkylammonium species; zwitterionic substances such as ammonium alkyl sulfonates, ammonium alkyl carboxylates, and amphoacetates; and nonionic substances such as hydroxyl, sulfonyl, ethyleneoxy, amide, ureid, and amine oxide.

[0044] Specific examples of hydrophobic monomers include, but are not limited to, the following: Acrylic hydrophobic monomers with the following structure (II):

[0045] [ka] During the ceremony, ·R 21 These are linear, branched, or cyclic (C5-C50) alkyl, hydroxyalkyl, alkoxyalkyl, aryl, or aralkyl groups. ·R 25 is H, or methyl, or ethyl. p and q are, independently of each other, 2, 3, or 4. • r and s are independent of each other and range from 0 to 50. t is between 1 and 50.

[0046] In one embodiment, the hydrophobic monomer is R 21 The compound is a linear (C8-C20) alkyl compound according to structure II. In one embodiment, the hydrophobic monomer is p=0 and s=0, and R 21The compound is a linear or branched (C8-C20) alkyl group, according to structure II. In one embodiment, the hydrophobic monomer is a compound according to structure II, with p=2, s=0, and t=1.

[0047] Suitable ethylenically unsaturated hydrophobic monomers include the following: - Alkyl-(meth)acrylates containing at least one linear or branched (C5-C40) alkyl group per molecule, such as pentyl-(meth)acrylate, hexyl-(meth)acrylate, tridecyl-(meth)acrylate, myristyl-(meth)acrylate, cetyl-(meth)acrylate, stearyl-(methyl)acrylate, behenyl polyalkoxylated (meth)acrylate, and mixtures thereof. - Alkyl polyether (meth)acrylates containing at least one linear or branched (C5-C40) alkyl-polyether group per molecule, such as hexyl polyalkoxylylated (meth)acrylate, tridecyl polyalkoxylylated (meth)acrylate, myristyl polyalkoxylylated (meth)acrylate, cetyl polyalkoxylylated (meth)acrylate, stearyl polyalkoxylylated (methyl)acrylate, eicosyl polyalkoxylylated (meth)acrylate, behenyl polyalkoxylylated (meth)acrylate, merisyl polyalkoxylylated (meth)acrylate, tristyrylphenoxyl polyalkoxylylated (meth)acrylate, and mixtures thereof. - Alkyl polyether (meth)acrylamides containing at least one (C5-C40) alkyl-polyether substituent per molecule, for example, hexyl polyalkoxylated (meth)acrylamide, tridecyl polyalkoxylated (meth)acrylamide, myristyl polyalkoxylated (meth)acrylamide, cetyl polyalkoxylated (meth)acrylamide, stearyl polyalkoxylated (methyl)acrylamide, eicosyl polyalkoxylated (meth)acrylamide, behenyl polyalkoxylated (meth)acrylamide, mericyl polyalkoxylated (meth)acrylamide, and mixtures thereof. - Alkyl polyether vinyl esters, alkyl polyether vinyl ethers, or alkyl polyether vinyl amides containing at least one (C5-C40) alkyl polyether substituent per molecule, such as vinyl stearate polyalkoxylates, myristyl polyalkoxylated vinyl ethers, and mixtures thereof. -and any two or more mixtures of the alkyl-polyether acrylate, alkyl-polyether methacrylate, alkyl-polyether acrylamide, alkyl-polyether methacrylamide, alkyl-polyether vinyl ester, alkyl-polyether vinyl ether, and alkyl-polyether vinylamide. -Cyclohexyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, isodecyl (meth)acrylate, lauryl (meth)acrylate, isobornyl (meth)acrylate, benzyl (meth)acrylate, phenoxyethyl (meth)acrylate, tetrahydrofurfuryl (meth)acrylate, glycidyl (meth)acrylate, vinyl 2-ethylhexanoate, and N-tert-octyl (meth)acrylamide. -In one embodiment, the hydrophobic monomer is one or more alkyl-polyalkoxylated (meth)acrylates containing one linear or branched (C5-C40) alkyl-polyethoxylated group per molecule, more commonly (C10-C22) alkyl-polyethoxylated group, for example, decyl-polyethoxylated (meth)acrylate, tridecyl-polyethoxylated (meth)acrylate, myristyl-polyethoxylated (meth)acrylate, cetyl-polyethoxylated (meth)acrylate, stearyl-polyethoxy This includes (methyl)acrylate, eicosyl-polyethoxylated (meth)acrylate, behenyl-polyethoxylated (meth)acrylate, and more generally, decyl-polyethoxylated methacrylate, tridecyl-polyethoxylated methacrylate, myristyl-polyethoxylated methacrylate, cetyl-polyethoxylated methacrylate, stearyl-polyethoxylated methyl acrylate, eicosyl-polyethoxylated methacrylate, behenyl-polyethoxylated methacrylate, and mixtures thereof.

[0048] Salt-resistant thickening polymers include other monomers, such as ethylenically unsaturated monomers, such as acrylamide, dimethylacrylamide, and diacetone(meth)acrylamide; vinyl esters, such as vinyl acetate, vinyl propionate; N-vinylamides, such as N-vinylpyrrolidion, N-vinylcaprolactam, N-vinylformamide, and N-vinylacetamide; vinyl ethers, such as methyl vinyl ether, ethyl vinyl ether, butyl vinyl ether, and hydroxybutyl vinyl ether; and ethylenically unsaturated aryl compounds, such as styrene and acetamide. This may include oxyethyl (meth)acrylate, (meth)acrylamide, for example, (meth)acrylamide, N-methylol(meth)acrylamide, N-butoxyethyl(meth)acrylamide, N,N-dimethyl(meth)acrylamide, N-isopropyl(meth)acrylamide, N-tert-butyl(meth)acrylamide, and ethylenically unsaturated alkyl esters of dicarboxylic acid monomers, for example, butylmethyl maleate, dimethylaminoethyl(meth)acrylate, diethylaminoethyl(meth)acrylate, and tert-butylaminoethyl(meth)acrylate.

[0049] In one or more embodiments, the salt-resistant thickening polymer and / or dispersion polymer comprises a 2-acrylamido-2-methylpropanesulfonate (also known as AMPS) moiety. In some embodiments, the salt-resistant thickening polymer comprises an ammonium acryloyldimethyltaurate moiety. In one or more embodiments, the acrylate-containing polymer is not a homopolymer of the acrylate moiety. In some embodiments, the salt-resistant thickening polymer comprises polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyltaurate copolymer, sodium acryloyldimethyltaurate / VP crosspolymer, or a combination thereof. Polyacrylate crosspolymer-6 is available as Sepimax Zen® (INCI name: Polyacrylate Crosspolymer-6), which is supplied in powder form sold by Seppic. Hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer is available as Sepinov® EMT10 (INCI name: Hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer), also available in powder form sold by Seppic. Acryloyldimethyl taurate / VP crosspolymer and ammonium acryloyldimethyl taurate / VP copolymer are available from Clariant as Aristoflex® AVS and Aristoflex® AVC, respectively (INCI names: Sodium acryloyldimethyl taurate / VP crosspolymer and ammonium acryloyldimethyl taurate / VP copolymer). Further information on these polymers can be found in the table below.

[0050] [Table 1]

[0051] Examples of naturally derived salt-tolerant thickening polymers include, but are not limited to, cellulose, xanthan gum, carrageenan, galactomannan, guar, tara, cassia, sesbania, locust bean gum, gellan rubber, welan rubber, carob seed flour, guar seed flour, starch, arginate, carrageenan, gellan, pullulan, scleroglucan, schizophyllan, curdlan, diutan, dextran, welan, chitin, and their derivatives, particularly derivatives in the form of alkylation (e.g., methyl ether, ethyl ether, C12-18 alkyl ether), hydroxyalkylation (hydroxyethyl, hydroxypropyl, or mixed ether), and carboxymethylation.

[0052] In some embodiments, the salt-resistant thickening polymer and / or dispersion polymer is a cellulose-containing polymer; that is, the polymer contains a cellulose moiety. In further embodiments, the cellulose-containing polymer is a cellulose ether polymer. Examples of cellulose-containing polymers include, but are not limited to, hydroxyalkylcellulose, carboxyalkylcellulose, alkylcellulose, hydroxyalkylalkylcellulose, cationic hydroxyalkylcellulose, hydrophobic modified hydroxyalkylcellulose, or cationic hydrophobic modified hydroxyalkylcellulose. In further embodiments, the thickening and / or dispersion polymer includes hydroxyethylcellulose, carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, ethylcellulose, cationic hydroxyethylcellulose, hydrophobic modified hydroxyethylcellulose, or cationic hydrophobic modified hydroxyethylcellulose.

[0053] In some embodiments, the thickening polymer is a dispersion polymer. The term “dispersion” polymer means that a composition having such a polymer exhibits a yield stress. [As used herein, the term “yield value” means that the modulus of elasticity of the composition must be greater than the viscosity in the low strain / stress plateau region of the amplitude sweep. The yield stress is then considered as the stress at the crossover where G'=G'' and expressed in Pascals (Pa). In one or more embodiments, the compositions of the present invention exhibit a yield value of about 0.1 Pa or greater, or about 0.5 Pa or greater, or about 1.0 Pa or greater, or about 2.0 Pa or greater.

[0054] In some embodiments, the pH of the composition is in the range of about 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8 or 3.9 to about 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9 or 5. In some embodiments, the pH of the composition is in the range of about 3 to about 5, or about 3.5 to about 4.5. Compositions below these pH ranges are considered to be very acidic to the skin and generally function as chemical peels. Chemical peels may also have higher acid concentrations (e.g., about 50%) than those in the embodiments described herein and may have a viscosity similar to water.

[0055] Any preferred method may be used to apply the composition to the skin in need. For example, the composition may be applied directly from the package to the skin in need, applied by hand to the skin in need, transferred from a substrate such as a wipe or mask, or a combination of two or more of these. In other embodiments, the composition may be applied via a dropper, tube, roller, spray and patch, or added to water applied to a bath or otherwise to the skin. The composition may be applied in a variety of ways / forms, including but not limited to leave-on creams, masks and / or serums. In one or more embodiments, the composition is left on the skin after application. The composition may be left on for a period of at least 1, 5, 10, 24 or 48 hours.

[0056] Exemplary composition Any of the embodiments described herein can be combined in various combinations. Another aspect of the present invention relates to compositions suitable for the treatment of acne. In one or more embodiments, the composition is a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer and / or dispersion polymer, It contains, and the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition.

[0057] In another embodiment, the present invention relates to a composition for treating acne, a. Glycolic acid in an amount of approximately 2.5% to 7.5% by weight, b. Approximately 1% to 5% by weight of gluconolactone, c. Approximately 1% to 5% by weight of mandelic acid, d. Approximately 2.5% to 7.5% by weight of propylene glycol, e. Approximately 0.5% to 2% by weight of polyacrylate crosspolymer-6, f. Approximately 0.5% to 2% by weight of hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, The present invention relates to a composition for treating acne, comprising glycolic acid, gluconolactone, and mandelic acid, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than approximately 12% by weight of the total composition.

[0058] Other additives Various other materials may also be present in the composition used in accordance with the principles of the present invention. In certain embodiments, the composition comprises one or more topical application components selected from the group consisting of surfactants, chelating agents, emollients, moisturizers, conditioners, preservatives, emulsions, fragrances, and the like.

[0059] Emaculators are compounds that help maintain the soft, smooth, and supple appearance of the skin (for example, by remaining on the surface or stratum corneum of the skin to act as a lubricant). Examples of suitable emollients can be found in Chapter 35, pages 399-415 (Skin Feel Agents, by G. Zocchi) of the Handbook of Cosmetic Science and Technology (edited by A. Barel, M. Paye, and H. Maibach, published in 2001 by Marcel Dekker, Inc. New York, NY), and include, but are not limited to, petrolatum, hexyldecyl stearate, dimethicone, neopentyl glycol diheptanoate, and plant, nut, and vegetable oils (e.g., macadamia nut oil, rice bran oil, grape seed oil, palm oil, primrose oil, hydrogenated peanut oil, and avocado oil).

[0060] A humectant is a compound intended to increase the water content of the outermost layer of skin (e.g., a hygroscopic compound). Examples of suitable humectants can be found in Chapter 35, pages 399-415 (Skin Feel Agents, by G. Zocchi) of the Handbook of Cosmetic Science and Technology (edited by A. Barel, M. Paye, and H. Maibach, published in 2001 by Marcel Dekker, Inc. (New York, NY)), and include, but are not limited to, glycerin, sorbitol, or trehalose (e.g., α,α-trehalose, β,β-trehalose, α,β-trehalose), or their salts or esters (e.g., trehalose-6-phosphate).

[0061] A surfactant refers to a surface-active agent intended for cleansing or emulsifying. Examples of suitable surfactants can be found in Chapter 37, pages 431-450 (Classification of surfactants, by L. Oldenhove de Guertechin) of the Handbook of Cosmetic Science and Technology (edited by A. Barel, M. Paye, and H. Maibach, published in 2001 by Marcel Dekker, Inc. (New York, NY)), and include, but are not limited to, anionic surfactants such as sulfates, cationic surfactants such as betaine, amphoteric surfactants such as sodium cocoglycinate, and nonionic surfactants such as alkyl polyglucosides.

[0062] Examples of suitable chelating agents include those that can protect and preserve the compositions of the present invention. In certain embodiments, the chelating agent is ethylenediaminetetraacetic acid ("EDTA"), and in further embodiments, tetrasodium EDTA, which is commercially available from Dow Chemical Company (Midland, Michigan) under the trademark name "Versene 100XL".

[0063] Suitable preservatives include, for example, parabens, quaternary ammonium species, phenoxyethanol, benzoate, DMDM ​​hydantoin, organic acids, and phenoxyethanol, which are present in the composition in an amount of about 0 to about 1% or about 0.05% to about 0.5% based on the total weight of the composition.

[0064] Any of the commercially available pearlescent or opacifying agents are suitable for use in the composition. Examples of suitable pearlescent or opacifying agents include, but are not limited to, the following: (a) fatty acids having about 16 to about 22 carbon atoms, and (b) mono or diesters of either ethylene or propylene glycol; (a) fatty acids having about 16 to about 22 carbon atoms, and (b) mono or diesters of polyalkylene glycol of the formula: HO-(JO)aH (wherein J is an alkylene group having about 2 to about 3 carbon atoms, and a is 2 or 3); aliphatic alcohols containing about 16 to about 22 carbon atoms; aliphatic esters of the formula: KCOOCH2L (wherein K and L independently contain about 15 to about 21 carbon atoms); inorganic solids insoluble in the shampoo composition, and mixtures thereof.

[0065] Any fragrance composition suitable for use on the skin may be used in accordance with the present invention.

[0066] Any suitable carrier may be used in the composition. In particular, the carrier is a cosmetic-acceptable carrier. As will be recognized by those skilled in the art, a cosmetic-acceptable carrier includes a carrier that is free from excessive toxicity, incompatibility, instability, irritation, allergic reactions, etc., and is suitable for use in contact with the body, especially the skin. The safe and effective amount of the carrier is about 50% to about 99.999% of the composition, particularly about 80% to about 99.9%, more specifically about 99.9% to about 95%, and most specifically about 98% to about 99.8%.

[0067] The following are non-limiting examples of carriers. Other carriers can be formulated by those skilled in the art. In one embodiment, the carrier comprises water. In a further embodiment, the carrier may further comprise one or more aqueous or organic solvents. Examples of organic solvents, but not limited to, include dimethyl isosorbide; isopropyl myristate; cationic, anionic, and nonionic surfactants; vegetable oils; mineral oils; waxes; gums; synthetic and natural gelling agents; alkanols; and polyols. Examples of alkanols include, but are not limited to, those having about 2 to about 12 carbon atoms (e.g., about 2 to about 4 carbon atoms), such as isopropanol and ethanol. Examples of polyols include, but are not limited to, those having about 2 to about 15 carbon atoms (e.g., about 2 to about 10 carbon atoms), such as propylene glycol. The organic solvent may be present in the carrier in an amount of about 1% to about 99.99% (e.g., about 20% to about 50%) of the total weight of the carrier. Water may be present in the carrier in an amount of about 5% to about 95% (e.g., about 50% to about 90%) relative to the total weight of the carrier (before use). The solution may contain any preferred amount of solvent, comprising about 40% to about 99.99%. Certain preferred solutions contain about 50% to about 99.9%, about 60% to about 99%, about 70% to about 99%, about 80% to about 99%, or about 90% to about 99% of the solvent.

[0068] A composition used in accordance with the principles of the present invention may further contain any of a variety of additional cosmetic surfactants. Examples of suitable additional surfactants include skin whitening agents, darkening agents, additional anti-aging agents, tropoelastin promoters, collagen promoters, anti-acne agents, gloss modifiers, antimicrobial agents (e.g., anti-yeast agents, antifungal agents, and antibacterial agents), anti-inflammatory agents, antiparasitic agents, topical analgesics, sunscreens, photoprotective agents, antioxidants, keratolytic agents, detergents / surfactants, moisturizers, nutrients, vitamins, energy enhancers, antiperspirants, astringents, deodorants, hair removal agents, hair growth enhancers, hair growth retarders, stabilizers, hydration enhancers, efficacy enhancers, anti-callus agents, skin conditioning agents, anti-cellulite agents, odor inhibitors (e.g., odor masking agents), or pH modifiers.

[0069] Examples of acceptable active substances as various suitable cosmetic additions include: benzoyl peroxide, D-panthenol; avobenzone (Parsol 1789), bis-disulizole disodium (Neo Heliopan AP), diethylamino hydroxybenzoyl hexyl benzoate (Uvinul A Plus), ecamsul (Mexoryl SX), methyl anthranilate, 4-aminobenzoic acid (PABA), cinoxate, ethylhexyl triazone (Uvinul T150), homosalate, 4-methylbenzylidene camphor (Parsol 5000), octyl methoxycinnamate (Octinoxate), octyl salicylate (Octisalate), padimate O (Escalol 507), phenylbenzimidazole sulfonic acid (Ensulizole), polysilicone-15 (Parsol SLX), trolamine salicylate, bemotoridinol (Tinosorb) S) Benzophenone 1-12, dioxybenzone, drometrizole trisiloxane (Mexoryl XL), iscotridinol (Uvasorb HEB), octocrylene, oxybenzone (Eusolex 4360), sulisobenzone, bisoctrizole (Tinosorb Examples include UV filters such as (30) titanium dioxide and zinc oxide, but not limited to these; carotenoids; free radical scavengers; spin traps; retinoids and retinoid precursors (e.g., (30) retinol, retinoic acid and retinyl palmitate); ceramides; polyunsaturated fatty acids; essential fatty acids; enzymes; enzyme inhibitors; minerals; hormones (e.g., estrogen); steroids (e.g., hydrocortisone); 2-dimethylaminoethanol; copper salts (e.g., copper chloride); copper-containing peptides such as Cu: Gly-His-Lys, coenzyme Q10; amino acids (e.g., proline); vitamins; lactobionic acid; acetyl-coenzyme A; niacin; riboflavin; thiamine; ribose; electron transporters (e.g., NADH and FADH2); and other plant extracts (e.g., extracts of oats, aloe vera, feverfew, soybeans, and shiitake mushrooms), as well as derivatives and mixtures thereof.

[0070] Product form and packaging The compositions can be prepared in a wide variety of product forms. For example, but not limited to, compositions in the form of emulsions such as oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions are useful herein. These emulsions can cover a wide range of viscosities, for example, from about 100 cps to about 200,000 cps. In this application, two types of viscosity measurements are referred to: A) 20s in a rheometer at 25°C -1 A) Rheometer viscosity, measured as a steady-state value at the applicable shear rate, and B) Brookfield viscosity, measured at 5 or 10 RPM after 1 minute at 25°C in a 4-ounce jar using spindle RV#4 or RV#5. Unless otherwise specified, the viscosity referred to is rheometer viscosity.

[0071] Examples of suitable forms include solutions, suspensions, lotions, creams, serums, essences, gels, toners, sticks, sprays, ointments, cleansing solutions and solid soaps, shampoos, hair conditioners, pastes, foams, mousses, powders, shaving creams, wipes, patches, strips, powered patches, microneedle patches, bandages, hydrogels, film-forming products, facial and skin masks, makeup, liquid drops, and the like.

[0072] In one or more embodiments, the compositions described herein are in the form of a serum or lotion. As used herein, the terms “serum” or “lotion” mean a primarily water-containing topical formulation having a viscosity of about 1,000 cPs to 4,000 cPs, a light texture, and a fresh, watery feel. A lotion or serum typically contains at least one emollient in addition to a solvent. A lotion / serum may contain about 1% to about 20% (e.g., about 5% to about 10%) of an emollient(s) and about 50% to about 90% (e.g., about 60% to about 80%) of water.

[0073] In some embodiments, the compositions described herein are in the form of a cream. As used herein, the term “cream” means a viscous, primarily water-containing topical formulation having a viscosity of about 2,000 cPs to 8,000 cPs. A cream typically contains about 5% to about 50% (e.g., about 10% to about 20%) of an emollient(s) and about 45% to about 85% (e.g., about 50% to about 75%) of water.

[0074] In one or more embodiments, the compositions described herein are in the form of ointments. As used herein, the term “ointment” means a topical preparation having a thick texture and a viscosity of about 10,000 cPs to about 40,000 cPs, primarily containing oils. The ointment may contain an animal oil, vegetable oil, or synthetic oil, or a simple base of semi-solid 10 hydrocarbons. The ointment may contain about 2% to about 10% of emollients and about 0.1% to about 2% of thickeners.

[0075] Compositions useful for the present invention can also be formulated as emulsions. When the carrier is an emulsion, about 1% to about 10% (for example, about 2% to about 5%) of the carrier contains emulsifiers (or multiple emulsifiers). The emulsifiers may be nonionic, anionic, or cationic.

[0076] The lotion and cream can be formulated as an emulsion. The lotion typically contains 0.5% to about 5% emulsifier(s), and the cream typically contains about 1% to about 20% (e.g., about 5% to about 10%) emollient(s), about 20% to about 80% (e.g., about 30% to about 70%) water, and about 1% to about 10% (e.g., about 2% to about 5%) emulsifier(s).

[0077] Single-phase emulsion skincare preparations such as lotions and creams, oil-in-water and water-in-oil, are well known in the art and are useful in the present invention. Multiphase emulsion compositions, such as water-in-oil or oil-in-water, are also useful in the present invention. Generally, such single-phase or multiphase emulsions contain water, a emollient, and an emulsifier as essential components.

[0078] The compositions of the present invention can also be formulated as gels. As used herein, the term “gel” means a viscous, primarily water-containing topical formulation containing a dispersion polymer and exhibiting a yield value of about 0.1 Pa or greater. The gel may contain a gelling agent. Such a gel typically contains about 0.1% to 5% by weight of such a gelling agent.

[0079] The compositions of the present invention can also be formulated into solid formulations (e.g., wax-based sticks, solid soap compositions, powders, or wipes). The compositions of the present invention may also be combined with solid, semi-solid, or soluble substrates (e.g., wipes, masks, pads, gloves, or strips).

[0080] The compositions described herein may be provided to consumers in containers such as bottles, tubes, etc. Individual packets containing measured portions of the compositions may also be used. A pump, a squeeze valve, or a removable screw cap may be used to dispense the compositions from the bottles. [Examples]

[0081] Examples 1A-C: Composition and properties Several compositions were prepared and evaluated as shown below. The viscosity values shown in the Results section of the Examples section are Brookfield viscosities and were measured using a Brookfield viscometer DV-II+PRO. For E1 - 3, an RVT spindle #4 at 5 rpm was used and the value was read after 1 minute. For E4 - E22, an RVT spindle #5 at 5 rpm was used and the value was taken after 1 minute. All measurements were performed at 22 °C in a 4-ounce glass jar.

[0082] E1 - 3 were prepared according to the following protocol. Premix A: Add 10% water, propylene glycol, glycolic acid, glucono delta lactone, mandelic acid, and salicylic acid (if included). Mix for at least 1.5 hours. Adjust the pH of this premix to 3.8 using 20% sodium hydroxide solution. Main phase: Add water, chelating agent, hydroxyethyl acrylate / sodium acryloyldimethyltaurate copolymer, polyacrylate cross polymer - 6. Start the homogenizer and add the other ingredients. Homogenize until the formulation is homogeneous, there are no undissolved particles, and an appropriate emulsion is formed.

[0083] Compositions E4 - E17 were prepared according to the following protocol. Acid premix: Add 10% water, propylene glycol, glycolic acid, glucono delta lactone, mandelic acid, and salicylic acid (if included). Mix for at least 1.5 hours. Adjust the pH of this premix to 3.5 - 3.8 using 20% sodium hydroxide solution. Main phase: Add water, polymer(s) (hydroxyethyl acrylate / sodium acryloyldimethyltaurate copolymer and polyacrylate cross polymer - 6, or ammonium acryloyldimethyltaurate / carboxyethyl acrylate cross polymer or sodium acryloyldimethyltaurate / VP cross polymer or hydroxyethyl cellulose). For E15 where hydroxyethyl cellulose was used, add 1,3 - butylene glycol to the main phase and heat the main phase to 75 oHeat to C. Homogenize the formulation in a homogenizer until uniform and no undissolved particles remain. Add the acid(s) premix and mix for 15 minutes. Add the other ingredients. Homogenize until uniform, no undissolved particles remain, and a suitable emulsion is formed. Adjust the pH to 3.4-4.0 using a 20% sodium hydroxide solution. For E1-3, adjust the pH of the formulation to 3.8.

[0084] [Table 2] 1.Sepimax Zen(trademark) 2.Sepinov(TM) EMT 10 3. A blend of Xiameter® PMX-200 silicone liquid, Dow Corning® Q7-9120 silicone liquid, and Dowsil® 9041 silicone elastomer blend.

[0085] As can be seen from the table above, compositions E1-12, containing a total amount of AHA, PHA, and (optionally) BHA acids of approximately 10.5 weight percent or less in combination with various levels of salt-tolerant thickening polymers, resulted in different formulations (lotions or serums (E1-E3), lotions (E4-E6), creams (E5, E6), or ointments (E7-12)). All viscosities were measured by the method described above.

[0086] Example 1B: Effect of polymer type on viscosity Five compositions were prepared according to the table below, and their viscosity was measured.

[0087] [Table 3] 1.Sepimax Zen(trademark) 2.Sepinov(TM) EMT 10 3. Aristoflex® AVC 4. Aristoflex® AVS

[0088] As can be seen from the table above, viscosity was increased according to the desired product form by using polymers with different properties. Compositions containing acrylate-based crosspolymers such as acryloyldimethyltaurate / VP copolymer (E16, E17), combinations of polyacrylate crosspolymer-6 and hydroxyethyl acrylate / sodium acryloyldimethyltaurate copolymer (E13, E14), and cellulosic polymers such as hydroxyethyl cellulose (E15) were prepared and their viscosities were measured. Furthermore, compositions formulated using sodium acryloyldimethyltaurate / VP crosspolymer (E16) showed higher viscosity than compositions formulated using ammonium acryloyldimethyltaurate / carboxyethyl acrylate at the same polymer concentration, and therefore, sodium acryloyldimethyltaurate / VP crosspolymer was deemed a more effective viscosity enhancer.

[0089] Example 1C: Effect of acid addition on viscosity Five samples were prepared according to the table below.

[0090] [Table 4] 1.Sepimax Zen(trademark) 2.Sepinov(TM) EMT 10

[0091] E18-22 were prepared according to the following protocol: Acid premix: Add 10% water, propylene glycol, glycolic acid and / or gluconolactone and / or mandelic acid. Mix for at least 1.5 hours. Adjust the pH of this premix to 3.5-3.8 using a 20% sodium hydroxide solution. Main phase: Add water, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, and polyacrylate crosspolymer-6. Homogenize the formulation in a homogenizer until uniform and no undissolved particles remain. Add the acid(s) premix and mix for 15 minutes, then adjust the pH to 3.4-4.0 using a 20% sodium hydroxide solution.

[0092] As can be seen from the table above, the addition of acid reduces viscosity compared to the formulation without acid (E18). The addition of glycolic acid in E19 showed the greatest decrease in viscosity compared to gluconolactone in E20 or mandelic acid in E21. At the same acid concentration, compositions containing glycolic acid required the largest amount of sodium hydroxide to adjust the pH to the desired value compared to gluconolactone and / or mandelic acid. Therefore, the example using glycolic acid (E19) contains the largest amount of salt that has the strongest effect on the polymer when reducing viscosity. The combination of gluconolactone and mandelic acid in E22 shows an additive effect, and therefore, a further decrease in viscosity requires more polymer to effectively increase viscosity.

[0093] Example 1D: Effect of polymer selection on stability Thirteen samples (six comparative samples and seven samples of the present invention) with the components shown in the table below were prepared, and their stability, rheometer viscosity, and yield were then evaluated. Stability was determined by the presence or absence of separation after 1 month at 50°C.

[0094] Samples were prepared according to the following protocol: Premix A: Add 10% water, propylene glycol, glycolic acid, gluconolactone, mandelic acid, and salicylic acid. Mix for at least 1.5 hours. Adjust the pH of this premix to 3.8 using a 20% sodium hydroxide solution. Main phase: Add water, chelating agent, and polymer(s) and mix until homogeneous (heat to 80°C if necessary). Start the homogenizer and add the remaining components. Homogenize until the formulation is uniform, there are no undissolved particles, and a suitable emulsion is formed. Adjust the pH to 3.6–4.0 using a 20% sodium hydroxide solution. All formulations have a salt content greater than 2%.

[0095] [Table 5] 1. Carbopol (registered trademark) Aqua SF-1 2. Carbopol (registered trademark) Aqua SF-2 3. Carbopol (registered trademark) Ultrez 20 4. Carbopol (registered trademark) Ultrez 10 5.Avalure(TM) Flex-6 6. A blend of Xiameter® PMX-200 silicone liquid, Dow Corning® Q7-9120 silicone liquid, and Dowsil® 9041 silicone elastomer blend.

[0096] [Table 6]

[0097] [Table 7] 1.Sepimax Zen(trademark) 2.Sepinov(TM) EMT 10 3. Aristoflex (registered trademark) Silk 4. Aristoflex (registered trademark) HMB 5. Rheocare XGN 6. Benecel K200M 7. A blend of Xiameter® PMX-200 silicone liquid, Dow Corning® Q7-9120 silicone liquid, and Dowsil® 9041 silicone elastomer blend.

[0098] [Table 8]

[0099] As can be seen from the table above, comparative compositions E23-28 were all unstable, while compositions E29-34 of the present invention were all stable. Here, stability means that the samples passed an accelerated stability test at 50°C for one month, showed no visual changes such as phase separation, and showed no significant changes in pH and viscosity. Since the compositions were all similar except for variations in polymer selection, the above data is useful regarding polymers that can be used to obtain stable preparations. All formulations of the present invention are characterized by the use of salt-tolerant polymers, particularly either sulfonate-containing or cellulosic components, whereas the comparative formulations are not.

[0100] As can be seen from the table above, compositions E29-34 containing various levels of salt-tolerant thickening polymers resulted in different formulations (lotion or serum (E31), cream (E32), or ointment (E29, E30, E33, E34)). All viscosities were measured by the method described above.

[0101] As can be seen from the table above, compositions E29 to E33 contain dispersed polymers and are therefore in gel form, exhibiting a yield value of approximately 0.1 Pa or higher.

[0102] Examples 2A-D: Clinical research A 12-week single-center, evaluator-blinded, randomized controlled clinical trial was conducted to evaluate the efficacy and tolerability of the compositions of the present invention (E1 and E2) in improving acne and facial appearance in patients with mild to moderate acne vulgaris. The breakdown of the compositions is reproduced in the table below. E1 and E2 are identical except that E1 contains salicylic acid, while E2 contains water instead of salicylic acid. 35 patients completed treatment with E1, and 32 patients completed treatment with E2.

[0103] [Table 9] 1.Sepinov(TM) EMT 10 2.Sepimax Zen(trademark) 3. A blend of Xiameter® PMX-200 silicone liquid, Dow Corning® Q7-9120 silicone liquid, and Dowsil® 9041 silicone elastomer blend.

[0104] Participants received their assigned treatment once daily (evening) during the first week, followed by twice daily (morning and evening) for the remainder of the study. Study investigators assessed acne disease variables, overall acne assessment, and additional clinical stepwise efficacy. Tolerance was assessed by the principal investigator and by self-assessment. The results are shown in the table below. The data show the total percentage of participants who showed improvement in at least one sub-attribute of the larger benefit bucket between both treatments across various attributes.

[0105] [Table 10]

[0106] As the results show, the treatment provided a statistically and clinically significant reduction in total disease variables (inflammatory and non-inflammatory) over the 12-week clinical study, starting at week 2, according to the investigator's grading, and there was no statistically significant difference in total disease variables between treatments A and B at week 12. In addition, both treatments improved redness of inflammatory lesions, skin surface roughness, and overall skin discoloration, and there was no statistically significant difference in grading at week 12. Both products were found to be well-tolerated without any statistically significant increase in any of the assessed tolerance attributes. The degree to which the products were well-tolerated was also surprising, considering the relatively high acid content of the products.

[0107] Examples 3A-C: Microbiological Research Two compositions of the present invention were tested against two placebo compositions to evaluate their effects on Propionibacterium acnes in both planktonic and biofilm states. The two compositions of the present invention are the same E1 and E2 described above. E1 and E2 are identical except that E1 contains salicylic acid, while E2 contains water instead of salicylic acid. The two placebo compositions correspond to E1 and E2, except that the placebo compositions do not contain propylene glycol or any acid. Placebo 1 has a pH of 4.5, which corresponds to the pH obtained if the component is removed without any additional pH adjustment. Placebo 2 is pH-adjusted to 3.8, which is the pH of E1 and E2, to account for any pH effect. The breakdown of the components of the compositions is shown in the table below.

[0108] [Table 11] 1.Sepinov(TM) EMT 10 2.Sepimax Zen(trademark) 3. A blend of Xiameter® PMX-200 silicone liquid, Dow Corning® Q7-9120 silicone liquid, and Dowsil® 9041 silicone elastomer blend.

[0109] Placebo 1 was prepared by adding water, a chelating agent, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, and polyacrylate crosspolymer-6. The mixture was then homogenized in a homogenizer, followed by the addition of the other components. The mixture was homogenized until the formulation was uniform, no undissolved particles remained, and a suitable emulsion was formed. Placebo 2 was prepared in the same manner as placebo 1, except that the pH was adjusted to 3.8 using a citric acid solution.

[0110] Example 3A: Effect on planktonic bacteria Planktonic bacteria were treated with E1-2 and placebo 1-2, and their effects were evaluated. The protocol used is described below.

[0111] Assay: Propionibacterium acnes (C. acnes) microbial sterilization time assay (standard plankton assay method) Test organism: Propionibacterium acnes ATCC 11827 Experimental procedure: Preparation of organisms: Prepare the biological inoculum by directly preparing a suspension of isolated colonies in sterile saline from agar plates. a. Using a spectrophotometer, target approximately 1.0 OD600 on the spectrophotometer for a suspension of approximately 10⁸–10⁹ CFU / mL. Further dilute to 10⁷ CFU / mL and 10⁵ CFU / mL in saline. 1:50 Neutralizing Agent Verification: Weigh 0.2 grams of the test sample and dilute it 1:50 in 9.8 mL of neutralizing agent. Prepare control tubes containing 9.8 mL of neutralizing agent and 0.2 mL of physiological saline. Add 100 μL of inoculum (105 CFU / mL of the standardized inoculum mentioned above) to all neutralizing and control tubes to obtain concentrations of 10–100 CFU / mL. After 10 minutes, add 0.1 mL to a fixed volume and spread the plate in double rows on an RCA plate. Incubate anaerobically at 35 ± 2.5°C for 5–7 days. Count the colonies and calculate the average CFU / mL. Recovery of neutralizing agent with a CFU / mL lower than 50% CFU / mL compared to the inoculated control indicates toxicity.

[0112] Microbial death time test Weigh 5 grams of each test sample into a sterile sample cup. Inoculate each sample cup with 50 μL of inoculant (107 CFU / mL). Start the timer and mix thoroughly. Sampling after 10 minutes. After the time has elapsed, transfer 0.2 grams of the inoculated test sample to 9.8 mL of neutralizing solution. Perform the same procedure with a blank sample of physiological saline.

[0113] Dilution and Plating: After the initial 1:50 dilution, perform another 1:50 dilution in physiological saline. Using 0.1 mL of the initial 1:50 dilution as a constant volume, spread the plate in a double row on an RCA plate. Prepare all plates after the initial 1:50 dilution as spot plates. Divide the agar plate into quarters by marking the bottom of the plate. Prepare a double row of plates for each sample. Each plate will hold up to five dilutions of one sample. Use a multi-dispenser pipette to draw up 100 μL of sample. Dispense five 10 μL spots into one of the quarters of the plate. Distribute the next five 10 μL spots onto one of the quarters of the replica plate. Continue with each dilution required for each sample.

[0114] After the liquid has been absorbed, invert the plate and incubate it in an anaerobic chamber at 35±2°C for 5-7 days until clear colonies are observed. Count the colonies using an automated colony counter and calculate the CFU / mL sample.

[0115] result

[0116] [Table 12]

[0117] As can be seen from the table above, both placebos 1 and 2 showed nearly the same bacterial count as the untreated control. In contrast, the bacterial counts of E1 and E2 in the present invention were below the detection limit. This indicates that E1 and E2 are effective in killing plankton acnes (C. acnes) bacteria. Furthermore, since E2 did not contain salicylic acid but still showed a high mortality rate, the presence of glycolic acid, gluconolactone, and mandelic acid is remarkably effective on its own in killing plankton acnes (C. acnes) bacteria.

[0118] Example 3B: Effect on biofilms Bacteria in a biofilm state were treated with E1-2 and placebo 1-2, and the effects were evaluated. The protocol used followed ASTM E2647-13: "Standard Test Method for Quantification of Pseudomonas aeruginosa Biofilm Grown Using Drip Flow Biofilm Reactor with Low Shear and Continuous Flow," which is also described below.

[0119] Preparation of *Propionibacterium acnes* (C. acnes) biofilm Standard *Propionibacterium acnes* (ATCC) 11827 cultures grown in reinforced Clostridium media (RCM) (Remel, Lenexa, KS) were used as seed cultures for biofilm formation. The biofilms were grown on half of a soda-lime glass microscope slide (VistaVision®, VWR International) in RCM growth medium supplemented with olive oil, oleic acid, and squalene. The biofilms were incubated anaerobically at 32.5±2.5°C for 72±0.5 hours.

[0120] Treatment of *Propionibacterium acnes* (C. acnes) biofilm with a clear skin formulation: After 72 ± 0.5 hours, the biofilm was removed from anaerobic conditions and treated with 1 gram of the test product for 10 minutes. Untreated biofilm served as a negative control in each test. After treatment, the biofilm and test product were immediately scraped off half of the slide and collected in neutralizing broth (TAT Broth, Remel) according to ASTM E2647-13 (modified procedure for *Propionibacterium acnes* biofilm). After collecting the biofilm and test product in neutralizing broth (considered as a 100-fold dilution), serial dilutions were performed with 0.85% physiological saline and seeded onto reinforced Clostridium agar (RCA). The plates were incubated anaerobically at 32.5 ± 2.5°C for 5–7 days. After incubation, the colonies on the plates were counted and the average CFU / cm2 was calculated (representing viability).

[0121] result

[0122] [Table 13]

[0123] [Table 14]

[0124] As can be seen from the table above, both placebos 1 and 2 showed nearly the same bacterial count as the untreated control. In contrast, the bacterial counts of E1 and E2 of the present invention were much lower. This demonstrates that E1 and E2 are effective in killing acne bacteria (C. acnes) in a biofilm state. These results are surprising, as bacteria are known to be more difficult to kill in biofilms. Furthermore, since E2 did not contain salicylic acid but still showed a high killing rate, the presence of glycolic acid, gluconolactone, and mandelic acid alone is effective in killing acne bacteria (C. acnes) in a biofilm state.

[0125] Example 3C: Biofilm disruption test The destructive efficacy of formulations according to one or more embodiments of the present invention was investigated against biofilm-presenting biological acne bacteria (C. acnes) ATCC 11827. The composition of the present invention (E1') was tested together with a placebo composition (placebo 2, same as above) and a sterile water control treatment. All were evaluated for their effect against biofilm-presenting acne bacteria (C. acnes). Placebo 2 is identical to E1', except that the placebo composition does not contain propylene glycol or any acid. Both the composition of the present invention (E1') and the placebo composition (placebo 2) were pH-adjusted to 3.8 to account for any pH effect. The breakdown of the compositional components is shown in the table below.

[0126] [Table 15]

[0127] The effectiveness of biofilm disruption was evaluated by treating Propionacterium acnes bacteria in a biofilm state with E1', placebo 2, and sterile water controls. The assay used was developed according to Holmberg, A. et al. "Biofilm Formation by Propionacterium acnes is a Characteristic of Invasive Isolates. Clin Microbiol Infect 2009;15:787-795," and is described below.

[0128] Preparation of *Propionibacterium acnes* (C. acnes) biofilm Standard *Propionibacterium acnes* (ATCC) 11827 cultures grown in reinforced Clostridium medium (RCM) (Remel, Lenexa, KS) were used as seed cultures for biofilm formation. The biofilms were grown in CoStar 96-well tissue culture treatment plates (Corning, Fisher Scientific, Pittsburgh, PA) in RCM growth medium supplemented with olive oil, oleic acid, and squalene. The biofilms were incubated in a 5% CO2 atmosphere for 72 ± 0.5 hours at 32.5 ± 2.5°C.

[0129] Treatment of *Propionibacterium acnes* (C. acnes) biofilms with test compositions: After 72 ± 0.5 hours, the biofilm was removed from the 5% CO2 atmosphere and treated with 200 μL of test composition (E1' and placebo 2, respectively), diluted 1:5 with sterile water, for 30 seconds at room temperature. Biofilms treated with sterile water alone served as negative controls in each test. After treatment, the biofilm and test composition were gently aspirated from the wells, and the wells were then gently washed with 0.1% peptone water and dried ("fixed") for 60 minutes. After fixation, the biofilm was stained with 1.0% crystal violet solution at room temperature for 15–20 minutes. After staining, excess crystal violet solution was decanted, and each well was gently rinsed with sterile water. Then, solvent (ethanol) was added to each well for 30 minutes. The solubilized dye was then dispensed into a new 96-well plate, and the mean optical density (OD) at 595 nm was measured. 595nm ) represents biomass, therefore the optical density (OD) at 595nm 595nm The absorbance was measured at ).

[0130] result

[0131] [Table 16]

[0132] As can be seen from the table above, the control (sterilized water) and placebo 2 showed average optical densities (representing average biomass) of 0.902 and 0.792, respectively. In contrast, E1' of the present invention showed a much lower average biomass of 0.678. This demonstrates that E1' is effective in disrupting *Propionibacterium acnes* (*C. acnes*) bacteria in a biofilm state. These results are surprising, as disrupting the structure of biofilms is often difficult.

[0133] While various aspects of this disclosure have been illustrated and described by examples, it will be understood that the inventions described in the claims herein are not limited thereto and can be embodied in various ways according to the claims and / or any derivative patent applications presented herein.

[0134] [Implementation Method] (1) A composition for treating acne, a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer, A composition for treating acne, comprising glycolic acid, gluconolactone, and mandelic acid, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition. (2) The composition according to Embodiment 1, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is at least about 2% by weight of the whole composition. (3) The composition according to Embodiment 1 or 2, wherein the glycol is selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof. (4) The composition according to any one of Embodiments 1 to 3, in the form of a lotion. (5) A composition according to any one of Embodiments 1 to 4, having a rheometer viscosity of about 2,000 to about 18,000 cPs at 22°C.

[0135] (6) A composition according to any one of Embodiments 1 to 5, having a rheometer viscosity of about 8,000 to about 10,000 cPs at 22°C. (7) A composition according to any one of embodiments 1 to 6, having a pH of approximately 3 to approximately 5. (8) The composition according to any one of Embodiments 1 to 7, further comprising about 0.5% to about 5% by weight of salicylic acid. (9) A composition according to any one of Embodiments 1 to 7, which is substantially free of salicylic acid. (10) A composition according to any one of Embodiments 1 to 9, which is substantially free of lactic acid.

[0136] (11) The composition according to any one of Embodiments 1 to 10, wherein the salt-resistant thickening polymer contains a naturally derived polymer, or the salt-resistant thickening polymer contains a sulfonate group. (12) The composition according to any one of Embodiments 1 to 11, wherein the salt-resistant thickening polymer is selected from the group consisting of polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer and combinations thereof. (13) The composition according to any one of Embodiments 1 to 12, wherein the salt-resistant thickening polymer comprises hydroxyethylcellulose. (14) A composition for treating acne, a. Glycolic acid in an amount of approximately 2.5% to 7.5% by weight, b. Approximately 1% to 5% by weight of gluconolactone, c. Approximately 1% to 5% by weight of mandelic acid, d. Approximately 2.5% to 7.5% by weight of propylene glycol, e. Approximately 0.5% to 2% by weight of polyacrylate crosspolymer-6, f. Approximately 0.5% to 2% by weight of hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, A composition for treating acne, comprising glycolic acid, gluconolactone, and mandelic acid, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 12% by weight of the total composition. (15) The composition according to Embodiment 14, in the form of a lotion.

[0137] (16) The composition according to Embodiment 14 or 15, having a rheometer viscosity of about 2,000 to about 18,000 cPs at 22°C. (17) A composition according to any one of embodiments 14 to 16, having a rheometer viscosity of about 8,000 to about 10,000 cPs at 22°C. (18) A composition according to any one of embodiments 14 to 17, having a pH of about 3 to about 5. (19) The composition according to any one of embodiments 14 to 18, further comprising about 0.5% to about 5% by weight of salicylic acid. (20) A composition according to any one of embodiments 14 to 18, which is substantially free of lactic acid.

[0138] (21) A method for treating acne, A method for treating acne, comprising contacting skin requiring such treatment with a composition comprising a first alpha-hydroxy acid, a second alpha-hydroxy acid, and a polyhydroxy acid. (22) The method according to Embodiment 21, wherein the first α-hydroxy acid comprises glycolic acid, the second hydroxy acid comprises mandelic acid, and the polyhydroxy acid comprises gluconolactone. (23) The method according to Embodiment 21 or 22, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition. (24) The method according to any one of embodiments 21 to 23, wherein the total amount of acid in the composition is less than about 15% by weight of the total composition. (25) The method according to any one of embodiments 21 to 24, wherein the composition is left on the skin.

[0139] (26) The method according to any one of embodiments 21 to 25, wherein the composition is in the form of a lotion. (27) The method according to any one of embodiments 21 to 26, wherein the composition has a pH of about 3 to about 5. (28) The method according to any one of embodiments 21 to 27, wherein the composition further comprises a glycol selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol and hexanetriol, and copolymers and combinations thereof. (29) The method according to any one of embodiments 21 to 28, wherein the composition is substantially free of lactic acid. (30) The method according to any one of embodiments 21 to 29, wherein the composition is substantially free of salicylic acid.

[0140] (31) A method for treating acne, wherein the skin requiring such treatment a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer, A method for treating acne, comprising contacting a composition containing glycolic acid, gluconolactone, and mandelic acid, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition. (32) The method according to Embodiment 31, wherein the total amount of acid in the composition is less than about 15% by weight of the total composition. (33) The method according to Embodiment 31 or 32, wherein the composition is left on the skin. (34) The composition according to any one of embodiments 31 to 33, in the form of a lotion. (35) The composition according to any one of embodiments 31 to 34, wherein the composition has a pH of about 3 to about 5.

[0141] (36) The composition according to any one of embodiments 31 to 35, wherein the composition further comprises a glycol selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, and copolymers and combinations thereof. (37) A composition according to any one of embodiments 31 to 36, which is substantially free of lactic acid. (38) A composition according to any one of embodiments 31 to 37, which is substantially free of salicylic acid. (39) The composition according to any one of Embodiments 31 to 38, wherein the salt-resistant thickening polymer contains a naturally derived polymer, or the salt-resistant thickening polymer contains a sulfonate group. (40) The composition according to any one of embodiments 31 to 39, wherein the salt-resistant thickening polymer is selected from the group consisting of polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer and combinations thereof.

[0142] (41) A method for destroying a biofilm or killing bacteria contained in a biofilm, comprising applying a composition comprising a first α-hydroxy acid, a second α-hydroxy acid, and a polyhydroxy acid to a surface having a biofilm. (42) The method according to embodiment 41, wherein the surface is a surface on the skin. (43) The method according to embodiment 41 or 42, wherein the skin has acne. (44) The method according to any one of embodiments 41 to 43, wherein the biofilm contains Propionibacterium acnes. (45) The method according to any one of embodiments 41 to 44, wherein the first α-hydroxy acid comprises glycolic acid, the second hydroxy acid comprises mandelic acid, and the polyhydroxy acid comprises gluconolactone.

[0143] (46) The method according to any one of Embodiments 41 to 45, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the whole composition. (47) The method according to any one of embodiments 41 to 46, wherein the total amount of acid in the composition is less than about 15% by weight of the total composition. (48) The method according to any one of embodiments 41 to 47, wherein the composition is in the form of a lotion. (49) The method according to any one of embodiments 41 to 48, wherein the composition has a pH of about 3 to about 5. (50) The method according to any one of embodiments 41 to 49, wherein the composition further comprises a glycol selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol and hexanetriol, and copolymers and combinations thereof.

[0144] (51) The method according to any one of embodiments 41 to 50, wherein the composition is substantially free of lactic acid. (52) The method according to any one of embodiments 41 to 51, wherein the composition is substantially free of salicylic acid. (53) A method for destroying a biofilm or killing bacteria contained in a biofilm, wherein on a surface having a biofilm, a. Glycolic acid in an amount of approximately 0.1% to 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and, e. Salt-resistant thickening polymer, The composition includes, and the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition, and the application of the composition is included. The composition has a pH of about 3 to about 5. A method for destroying a biofilm, or killing bacteria contained in a biofilm, wherein the surface is the surface of the skin. (54) The method according to embodiment 53, wherein the skin has acne. (55) The method according to Embodiment 53 or 54, wherein the biofilm contains Propionibacterium acnes.

[0145] (56) The method according to any one of embodiments 53 to 55, wherein the total amount of acid in the composition is less than about 15% by weight of the total composition. (57) The method according to any one of embodiments 53 to 56, wherein the composition further comprises a glycol selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, and copolymers and combinations thereof. (58) The method according to any one of embodiments 53 to 57, wherein the composition is substantially free of lactic acid. (59) The method according to any one of embodiments 53 to 58, wherein the composition is substantially free of salicylic acid. (60) The method according to any one of embodiments 53 to 59, wherein the salt-resistant thickening polymer is selected from the group consisting of polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer and combinations thereof.

Claims

1. A method for treating acne, A method for treating acne, comprising contacting skin requiring such treatment with a composition comprising a first α-hydroxy acid, a second α-hydroxy acid, and a polyhydroxy acid.

2. The method according to claim 1, wherein the first α-hydroxy acid comprises glycolic acid, the second α-hydroxy acid comprises mandelic acid, and the polyhydroxy acid comprises gluconolactone.

3. The method according to claim 1 or 2, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition.

4. The method according to any one of claims 1 to 3, wherein the total amount of acid in the composition is less than about 15% by weight of the total composition.

5. The method according to any one of claims 1 to 4, wherein the composition is left on the skin.

6. The method according to any one of claims 1 to 5, wherein the composition is in the form of a lotion.

7. The method according to any one of claims 1 to 6, wherein the composition has a pH of about 3 to about 5.

8. The method according to any one of claims 1 to 7, wherein the composition further comprises a glycol selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof.

9. The method according to any one of claims 1 to 8, wherein the composition substantially does not contain lactic acid.

10. The method according to any one of claims 1 to 9, wherein the composition substantially does not contain salicylic acid.

11. A method for destroying a biofilm or killing bacteria contained in a biofilm, comprising applying a composition comprising a first α-hydroxy acid, a second α-hydroxy acid, and a polyhydroxy acid to a surface having a biofilm.

12. The method according to claim 11, wherein the surface is a surface on the skin.

13. The method according to claim 12, wherein the skin has acne.

14. The method according to any one of claims 11 to 13, wherein the biofilm contains Propionibacterium acnes.

15. The method according to any one of claims 11 to 14, wherein the first α-hydroxy acid comprises glycolic acid, the second α-hydroxy acid comprises mandelic acid, and the polyhydroxy acid comprises gluconolactone.

16. The method according to any one of claims 11 to 15, wherein the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition.

17. The method according to any one of claims 11 to 16, wherein the total amount of acid in the composition is less than about 15% by weight of the total composition.

18. The method according to any one of claims 11 to 17, wherein the composition is in the form of a lotion.

19. The method according to any one of claims 11 to 18, wherein the composition has a pH of about 3 to about 5.

20. The method according to any one of claims 11 to 19, wherein the composition further comprises a glycol selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof.

21. The method according to any one of claims 11 to 20, wherein the composition substantially does not contain lactic acid.

22. The method according to any one of claims 11 to 21, wherein the composition substantially does not contain salicylic acid.

23. A method for destroying a biofilm or killing bacteria contained in a biofilm, wherein on a surface having a biofilm, a. Glycolic acid in an amount of approximately 0.1% to approximately 7.5% by weight, b. Approximately 0.1% to 5% by weight of gluconolactone, c. Approximately 0.1% to 5% by weight of mandelic acid, d. Glycol and e. Salt-resistant thickening polymer and The composition includes, and the total amount of glycolic acid, gluconolactone, and mandelic acid is less than about 15% by weight of the total composition, and the application of the composition is included. The composition has a pH of about 3 to about 5. A method for destroying a biofilm, or killing bacteria contained in a biofilm, wherein the surface is the surface of the skin.

24. The method according to claim 23, wherein the skin has acne.

25. The method according to claim 23 or 24, wherein the biofilm contains Propionibacterium acnes.

26. The method according to any one of claims 23 to 25, wherein the total amount of acid in the composition is less than about 15% by weight of the total composition.

27. The method according to any one of claims 23 to 26, wherein the composition further comprises a glycol selected from the group consisting of glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, caprylyl glycol, glycerol, butanediol, and hexanetriol, as well as copolymers and combinations thereof.

28. The method according to any one of claims 23 to 27, wherein the composition substantially does not contain lactic acid.

29. The method according to any one of claims 23 to 28, wherein the composition substantially does not contain salicylic acid.

30. The method according to any one of claims 23 to 29, wherein the salt-resistant thickening polymer is selected from the group consisting of polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer and combinations thereof.

Images